Abstract
Chronic hepatitis C is one of the major causes of cirrhosis and hepatocellular carcinoma. The response to treatment in cirrhotics from PegIFN-based therapy is poor, thus the new options of treatment with direct acting antivirals (DAAs) continue showing decreased rates of sustained virological response (SVR), mainly in advanced cirrhosis. Some hypotheses are: impaired pharmacokinetics, pos…